Duration of antiviral immunity after smallpox vaccination

Nature Medicine

Volumn 9, Issue 9, 2003, Pages 1131-1137

  Hammarlund, Erika ^a   Lewis, Matthew W ^a   Hansen, Scott G ^a   Strelow, Lisa I ^a   Nelson, Jay A ^a   Sexton, Gary J ^b   Hanifin, Jon M ^b   Slifka, Mark K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH PROGRAM; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; MALE; MORBIDITY; MORTALITY; NORMAL HUMAN; PRIORITY JOURNAL; PROTECTION; SMALLPOX; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS IMMUNITY; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HALF-LIFE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; SMALLPOX VACCINE; T-LYMPHOCYTES; TIME FACTORS; VACCINIA VIRUS;

DNA VIRUSES; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 0141796316     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm917     Document Type: Article

References (50)

1. Henderson, D.A. The looming threat of bioterrorism. Science 283, 1279-1282 (1999).
2. Meltzer, M.I., Damon, I., LeDuc, J.W. & Millar, J.D. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis. 7, 959-969 (2001).
3. Gani, R. & Leach, S. Transmission potential of smallpox in contemporary populations. Nature 414, 748-751 (2001).
4. Kaplan, E.H., Craft, D.L. & Wein, L.M. Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl. Acad. Sci. USA 99, 10935-10940 (2002).
5. O'Toole, T., Mair, M. & Inglesby, T.V. Shining light on "Dark Winter". Clin. Infect. Dis. 34, 972-983 (2002).
6. Smith, G.L. & McFadden, G. Science and society. Smallpox: anything to declare? Nat. Rev. Immunol. 2, 521-527 (2002).
7. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z. & Ladnyl, I.D. in The Pathogenesis, Immunology, and Pathology of Smallpox and Vaccinia (World Health Organization, Geneva, 1988).
8. Mack, T.M., Noble, J. Jr & Thomas, D.B. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21, 214-218 (1972).
9. Sarkar, J.K., Mitra, A.C. & Mukherjee, M.K. The minimum protective level of antibodies in smallpox. Bull. World Health Organ. 52, 307-311 (1975).
10. Downie, A.W. & McCarthy, K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J. Hyg. 56, 479-487 (1958).
11. + T cells can be distinguished by their cytokine profiles and phenotypic markers. J. Immunol. 164, 208-216 (2000).
12. Nyerges, G., Hollos, I., Losonczy, G., Erdos, L. & Petras, G. Development of vaccination immunity in hospital personnel revaccinated at three-year intervals. Acta Microbiol. Acad. Sci. Hung. 19, 63-68 (1972).
13. el-Ad, B. et al. The persistence of neutralizing antibodies after revaccination against smallpox. J. Infect. Dis. 161, 446-448 (1990).
14. + T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J. Exp. Med. 197, 927-932 (2003).
15. + T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining. J. Immunol. Methods 262, 167-180 (2002).
16. McCarthy, K. & Downie, A.W. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J. Hyg. 56, 466-478 (1958).
17. Stienlauf, S. et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 17, 201-204 (1999).
18. Centers for Disease Control. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization practices (ACIP). Morb. Mortal. Wkly. Rep. 50, 1-25 (2001).
19. Frey, S.E., Newman, F.K., Yan, L. & Belshe, R.B. Response to smallpox vaccine in persons immunized in the distant past. J. Am. Med. Assoc. 289, 3295-3299 (2003).
20. Frey, S.E. et al. Dose-related effects of smallpox vaccine. N. Engl. J. Med. 346, 1275-1280 (2002).
21. + cytotoxic T lymphocytes and interferon-γ-producing T cells after smallpox vaccination. J. Infect. Dis. 185, 1657-1659 (2002).
22. CDC. Smallpox - Stockholm, Sweden, 1963. Morb. Mortal. Wkly. Rep. 12, 172, 174-176, 183, 188, 191, 220, 236 (1963).
23. Mack, T.M. Smallpox in Europe, 1950-1971. J. Infect. Dis. 125, 161-169 (1972).
24. Gayton, W. in The value of vaccination as shown by an analysis of 10,403 cases of smallpox (Gillett & Henty, London, 1885).
25. Hanna, W. in Studies in smallpox and vaccination (William Wood and Company, New York, 1913).
26. Hanna, W. & Baxby, D. Studies in smallpox and vaccination. 1913. Rev. Med. Virol. 12, 201-209 (2002).
27. Heiner, G.G. et al. A study of inapparent infection in smallpox. Am. J. Epidemiol. 94, 252-268 (1971).
28. Kempe, C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics 25, 176-189 (1960).
29. Czerny, C.P. & Mahnel, H. Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies. J. Gen. Virol. 71 (Pt. 10), 2341-2352 (1990).
30. Galmiche, M.C., Goenaga, J., Wittek, R. & Rindisbacher, L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254, 71-80 (1999).
31. Ramirez, J.C., Tapia, E. & Esteban, M. Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J. Gen. Virol. 83, 1059-1067 (2002).
32. Zinkernagel, R.M. & Althage, A. Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled. J. Exp. Med. 145, 644-651 (1977).
33. Derby, M., Alexander-Miller, M., Tse, R. & Berzofsky, J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166, 1690-1697 (2001).
34. Appay, V. et al. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168, 5954-5958 (2002).
35. + T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. J. Immunol. 170, 2205-2213 (2003).
36. + cytotoxic T-lymphocyte clones. J. Virol. 66, 2274-2280 (1992).
37. Erickson, A.L. & Walker, C.M. Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans. J. Gen. Virol. 74, 751-754 (1993).
38. Demkowicz, W.E.J., Littaua, R.A., Wang, J. & Ennis, F.A. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J. Virol. 70, 2627-2631 (1996).
39. Zarling, J.M. et al. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J. Immunol. 139, 988-990 (1987).
40. Breman, J.G. & Henderson, D.A. Diagnosis and management of smallpox. N. Engl. J. Med. 346, 1300-1308 (2002).
41. Perrin, L.H., Reynolds, D., Zinkernagel, R. & Oldstone, M.B. Generation of virus-specific cytolytic activity in human peripheral lymphocytes after vaccination with vaccinia virus and measles virus. Med. Microbiol. Immunol. (Berl.) 166, 71-79 (1978).
42. Perrin, L.H., Zinkernagel, R.M. & Oldstone, M.B. Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes. J. Exp. Med. 146, 949-969 (1977).
43. Kempe, C.H., Berge, T.O. & England, B. Hyperimmune vaccinial γ globulin. Pediatrics 18, 177 (1956).
44. Peirce, E.R., Melville, F.S., Downie, A.W. & Duckworth, M.J. Antivaccinial γ-globulin in smallpox prophylaxis. Lancet 2, 635-638 (1958).
45. Kempe, C.H. et al. The use of vaccinia hyperimmune γ-globulin in the prophylaxis of smallpox. Bull World Health Organ. 25, 41-48 (1961).
46. Slifka, M.K. & Ahmed, R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol. 4, 394-400 (1996).
47. Frelinger, J.A. & Garba, M.L. How durable are the immune responses after smallpox vaccination? N. Engl. J. Med. 347, 689-690 (2002).
48. Slifka, M.K. & Ahmed, R. Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay. J. Immunol. Meth. 199, 37-46 (1996).
49. Anderson, S.G. & Skegg, J. The international standard for anti-smallpox serum. Bull. World Health Organ. 42, 515-523 (1970).
50. Cutchins, E., Warren, J. & Jones, W.P. The antibody response to smallpox vaccination as measured by a tissue culture plaque technique. J. Immunol. 85, 275-283 (1960).